Zobrazit v EDS

KLK9 (kallikrein-related peptidase 9)

Uloženo v:
Podrobná bibliografie
Název: KLK9 (kallikrein-related peptidase 9)
Autoři: Adamopoulos, Panagiotis G, Scorilas, Andreas
Přispěvatelé: Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens. 157 01, Panepistimiopolis, Athens, Greece
Informace o vydavateli: ARMGHM - Atlas Génétique des Cancers
Rok vydání: 2017
Sbírka: I-Revues (E-Journals, INIST-CNRS)
Témata: Kallikreins, KLK9, KLK-L3, KLKL3, biomarker, proteolytic cascades, breast cancer, ovarian cancer, astrocytoma, Genes Section, Astrocytoma/metabolism/*pathology, Biomarkers, Tumor/metabolism, Brain Neoplasms/metabolism/*pathology, Humans, Kallikreins/*metabolism, Prognosis, Survival Analysis, Tissue Array Analysis/methods, Up-Regulation, Adult, Aged, Body Fluids/*metabolism, Enzyme-Linked Immunosorbent Assay
Popis: Kallikreins (KLKs) represent the largest cluster of serine peptidases, which is composed of 15 members (KLK1-15). The human kallikrein-related peptidase 9 gene (KLK9), like the rest of the KLK genes, encodes for a trypsin-like serine peptidase. Serine peptidases are a group of protein-cleaving enzymes that contain a serine residue in their active site. Kallikreins constitute a subfamily of serine peptidases that cleave kininogen and release vasoactive peptides (kinins). The human KLK9 gene is located at 19q13.41 and consists of 5 exons and 4 intervening introns. Although KLK9 expression has been detected in various normal human tissues, differences in mRNA and protein expression levels have been observed. Like other KLKs, KLK9 is found differentially expressed in multiple human malignancies. Clinical studies regarding the KLK9 expression analysis in breast cancer tissues have demonstrated that KLK9 mRNA expression possesses significant prognostic ability and therefore could be a strong, independent marker of favorable prognosis in patients with breast cancer. In addition, the prognostic potential of the KLK9 mRNA expression levels in ovarian cancer has been clarified, since patients with KLK9-positive tumors demonstrate significantly longer progression-free and overall survival in comparison with KLK9-negative patients. Finally, KLK9 could serve as a prognostic biomarker for patients diagnosed with high-grade astrocytoma, as its expression level is associated with decreased survival of patients. Although the precise localization and structure of the KLK9 gene has now been fully characterized, its functional roles and connections to human diseases are still incompletely understood and merit further investigation.
Druh dokumentu: article in journal/newspaper
Jazyk: English
ISSN: 1768-3262
Relation: Atlas of Genetics and Cytogenetics in Oncology and Haematology; http://AtlasGeneticsOncology.org/Genes/KLK9ID47324ch19q13.html; Panagiotis G, Adamopoulos; Andreas, Scorilas. KLK9 (kallikrein-related peptidase 9). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2017, 5, p. 173-175; http://hdl.handle.net/2042/68242; https://doi.org/10.4267/2042/68242
DOI: 10.4267/2042/68242
Dostupnost: http://hdl.handle.net/2042/68242
https://doi.org/10.4267/2042/68242
Rights: Open access resource - terms and conditions : http://irevues.inist.fr/utilisation
Přístupové číslo: edsbas.A7B9598E
Databáze: BASE
Popis
Abstrakt:Kallikreins (KLKs) represent the largest cluster of serine peptidases, which is composed of 15 members (KLK1-15). The human kallikrein-related peptidase 9 gene (KLK9), like the rest of the KLK genes, encodes for a trypsin-like serine peptidase. Serine peptidases are a group of protein-cleaving enzymes that contain a serine residue in their active site. Kallikreins constitute a subfamily of serine peptidases that cleave kininogen and release vasoactive peptides (kinins). The human KLK9 gene is located at 19q13.41 and consists of 5 exons and 4 intervening introns. Although KLK9 expression has been detected in various normal human tissues, differences in mRNA and protein expression levels have been observed. Like other KLKs, KLK9 is found differentially expressed in multiple human malignancies. Clinical studies regarding the KLK9 expression analysis in breast cancer tissues have demonstrated that KLK9 mRNA expression possesses significant prognostic ability and therefore could be a strong, independent marker of favorable prognosis in patients with breast cancer. In addition, the prognostic potential of the KLK9 mRNA expression levels in ovarian cancer has been clarified, since patients with KLK9-positive tumors demonstrate significantly longer progression-free and overall survival in comparison with KLK9-negative patients. Finally, KLK9 could serve as a prognostic biomarker for patients diagnosed with high-grade astrocytoma, as its expression level is associated with decreased survival of patients. Although the precise localization and structure of the KLK9 gene has now been fully characterized, its functional roles and connections to human diseases are still incompletely understood and merit further investigation.
ISSN:17683262
DOI:10.4267/2042/68242